Elevated IL-17A level is associated with poor overall survival following immune checkpoint inhibitors combined with targeted therapy in hepatocellular carcinoma with hyperbilirubinemia
BackgroundCombination therapy with programmed death-1 (PD-1) inhibitors and targeted therapy is a first-line treatment for advanced hepatocellular carcinoma (HCC). Patients with hyperbilirubinemia (total bilirubin > upper limit of normal) are often excluded from such regimens. This study aimed to...
Збережено в:
| Автори: | , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2026-04-01
|
| Серія: | Frontiers in Immunology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1791538/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|